缓慢生长的丘脑H3 K27M突变胶质瘤:手术干预前3年随访
本文报告一例39岁男性丘脑胶质瘤伴组蛋白H3赖氨酸27至甲硫氨酸(H3 K27M)突变,在发现肿瘤3年后才接受手术干预,术前未接受任何针对弥漫性中线胶质瘤H3 K27M突变型(DMG-K27M)的治疗。该病例反映了此类恶性肿瘤一种可能的自然病程,提示在缺乏干预情况下肿瘤生长缓慢且生存期延长(≥3年)。
要点
- DMG-K27M为WHO IV级肿瘤,平均生存期约1年,但本例未干预生存≥3年。
- 该病例术前未接受任何治疗,反映了DMG-K27M一种可能的自然病程。
- 对DMG-K27M需谨慎评估早期干预是否最佳。
核心结论
- 目前DMG-K27M尚无有效治疗选择。
- 本例未干预下肿瘤生长缓慢且生存期延长(≥3年),提示对H3 K27M突变的认识仍不足。
- 治疗DMG-K27M时需谨慎评估早期干预是否最佳。
研究设计与样本
- 个案报道:一例39岁男性丘脑胶质瘤伴H3 K27M突变。
- 患者在发现肿瘤3年后接受手术干预。
- 患者术前未接受任何针对DMG-K27M的治疗。
主要发现
- 该肿瘤为缓慢生长的丘脑胶质瘤伴H3 K27M突变。
- 未干预情况下生存期≥3年。
- 该病例反映了DMG-K27M一种可能的自然病程。
关键数值与推荐
- 2016年WHO中枢神经系统肿瘤分类将DMG-K27M列为新诊断实体。
- DMG-K27M无论组织病理学特征如何均分类为WHO IV级。
- DMG-K27M诊断后平均生存时间为1年。
临床怎么用
- 对DMG-K27M患者需谨慎评估早期干预是否最佳。
- 应认识到H3 K27M突变对病理生理、诊断、治疗和预后的影响尚不明确。
局限性
- 个案报道,结论不能推广至所有DMG-K27M患者。
- 仅反映一例患者的自然病程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 2016 World Health Organization Classification of Tumours of the Central Nervous System was revised to include a new diagnostic entity, diffuse midline glioma, H3 K27M-mutant (DMG-K27M), a highly aggressive tumor with a mean survival time of 1 year after diagnosis. DMG-K27M is classified as a World Health Organization grade IV tumor regardless of histopathologic features, and there is currently no effective treatment for it despite ongoing research. CASE DESCRIPTION: We present a case of a 39-year-old man with a slow-growing thalamic glioma with histone H3 lysine 27-to-methionine mutation. This patient received surgical intervention 3 years after the initial discovery of the tumor. Because the patient did not receive any preoperative treatment for DMG-K27M, this case reflects 1 possible natural course of progression for this type of malignancy. CONCLUSIONS: There are currently no effective therapeutic options for treatment of DMG-K27M. The slow tumor growth and prolonged survival time (≥ 3 years) in the absence of intervention in this case serve as a reminder that much is still not known about histone H3 lysine 27-to-methionine mutation and how it impacts the pathophysiology, diagnosis, treatment, and prognosis of the disease. Careful evaluation is warranted to determine if early intervention is the best approach when treating DMG-K27M.
引用
- Chanchotisatien A, Pan J, Du Z, et al. Slow-Growing Thalamic Glioma with Histone H3 Lysine 27-to-Methionine Mutation: 3-Year Follow-Up Before Surgical Intervention. World Neurosurg. 2019. PMID: 30981797. doi:10.1016/j.wneu.2019.04.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。